Skip to main content

Advertisement

Table 2 Effect of electron transport chain complex inhibitors on OCR and ECAR in PBMCs

From: Systemic Immuno-metabolic alterations in chronic obstructive pulmonary disease (COPD)

   HNS HS TS-COPD
Glucose OCR ATP Production (%) 61.3 (56.5–66.2) 50.7 (48.6–59.6)* 54.8 (48.8–57.3)**
Max Resp. Capacity (%) 91.9 (73.8–109.5) 80.2 (51.6–93.8) 72.1 (59.0–75.7)*
Spare Resp. Capacity (%) 87.5 (61.6–105.4) 57.1 (42.7–69.0)** 68.0 (57.8–77.3)*
Glucose ECAR Glycolytic Capacity (%) 315.6 (278.7–358.1) 194 (170–267.8) 198.2 (144.4–219.1) *
Glycolytic Reserve (%) 92.4 (65.8–102.6) 84.3 (72.2–110.6) 57.8 (49.7–64.5)*,##
Non-Glycolytic Acidification (%) 73 (63.4–80.3) 74.5 (65.7–92) 94.4 (83.9–99.9)**
Palmitate OCR ATP Production (%) 53.5 (47.9–72.4) 62.5 (52.7–75.9) 37.7 (31.4–45.8)***, ##
Max Resp. Capacity (%) 101.6 (94.3–118.9) 104.2 (98.3–130.7) 83.1 (56.3–86.5)**, ##
Spare Resp. Capacity (%) 66.7 (47.6–81.1) 65.3 (61.5–95.6) 38.5 (32.4–57.1)*, #
Non-fatty acid Mitochondrial Resp. (%) 30.8 (19.5–42.3) 38.6 (30.6–49.5) 37.4 (25.6–54.8)
  1. Data for ATP production, maximum respiratory capacity, spare respiratory capacity, glycolytic capacity and glycolytic reserve is represented as median % change in OCR/ECAR (Inter-quartile range). Non-glycolytic acidification and non-mitochondrial respiration is represented as percentage of baseline (before adding glucose or palmitate) ECAR and OCR, respectively. HNS Healthy non-smokers, HS Healthy smokers and TS-COPD Tobacco-smoking COPD subjects. * indicates p < 0.05, ** indicates p < 0.01 and *** indicates p < 0.001 as compared to HNS whereas, # indicates p < 0.05 and ## indicates p < 0.01 as compared to HS using the Mann-Whitney U test for between-group comparison